GTBP Stock — GT Biopharma Inc

GT Biopharma Inc (GTBP)

Updated October 16, 2026.

GTBP is a Stock. Its deepest 1-year drawdown was 73.8%.

GT Biopharma is a clinical-stage biopharmaceutical company developing immuno-oncology therapies based on its Tri-specific and Tetra-specific Killer Engager platforms, with product candidates in phase 1 trials for myeloid leukemias and solid tumors, as well as pre-clinical stage programs for autoimmune disorders. The company does not currently distribute to shareholders. GT Biopharma appeals primarily to investors seeking exposure to early-stage biotech development with high risk and potential for significant future returns, rather than those focused on current income.

GTBP performance

Returns are updating. GTBP's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 73.8%.

GTBP key facts

Asset type

Stock

Asset class

Equity

Inception date

11/05/1984

Distribution frequency

None

Last close

$7.03 (as of 2026-10-16)

Market cap

$14,489,196

Average volume

55232.0

Payment date

08/21/2017

Beta

0.855

Payout ratio

0.0%

Forward P/E

17.331

EPS

$-144.48

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

GTBP risks and drawbacks

The deepest 1-year drawdown on record here is 73.8%.

Who may consider GTBP — and who may not

It is a weaker fit for investors who need monthly cash flow (GTBP does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on GTBP

• All tickers starting with G

Tagged: Healthcare.

Frequently asked questions